TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate Efficacy and Safety of SAGE-547 in Participants With Severe Postpartum Depression (547-PPD-202B)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Key Inclusion Criteria:~* Participants must have ceased lactating at screening; or if still lactating or actively breastfeeding at screening, agreed to temporarily cease giving breastmilk to their infant(s) from just prior to receiving study drug through nine days (Day 12) after the end of the infusion~* Participants had a major depressive episode that began no earlier than the third trimester and no later than the first 4 weeks following delivery, as diagnosed by Structured Clinical Interview for DSM-IV Axis I Disorders (SCID-I)~* Participant had a HAM-D total score of ≥26 at screening and Day 1 (prior to dosing)~* Participant was ≤6 months postpartum at screening~* Participant was amenable to IV therapy~Key Exclusion Criteria:~* Active psychosis~* Attempted suicide associated with index case of postpartum depression~* Medical history of bipolar disorders, schizophrenia, and/or schizoaffective disorder.~Note: Other protocol-defined inclusion/exclusion criteria applied.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Participants received infusion rates equivalent to either the 60 micrograms per kilogram per hour (μg/kg/h) or 90 μg/kg/h group.
- SAGE-547 60 μg/kg/h (Type: EXPERIMENTAL): Participants received a 4-hour titration period of 30 μg/kg/h (0 to 4 hours), then 60 μg/kg/h (4 to 56 hours), followed by a taper to 30 μg/kg/h (56 to 60 hours).
- SAGE-547 90 μg/kg/h (Type: EXPERIMENTAL): Participants received a 4-hour dose titration period of 30 μg/kg/h (0 to 4 hours), then 60 μg/kg/h (4 to 24 hours), then 90 μg/kg/h (24 to 52 hours), followed by a taper to 60 μg/kg/h (52 to 56 hours), and 30 μg/kg/h (56 to 60 hours).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Open-label Study of the Efficacy and Safety of VESIcare® in Patients With Overactive Bladder Symptoms

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Symptoms of OAB (urgency, with or without urge incontinence, usually with frequency and nocturia) for ≥3 or more months.~* Patients may be included if they are on another OAB medication; however, patients must washout from other OAB medications for at least 7 days prior to receiving solifenacin succinate. Previous non-drug treatment of OAB is allowed if it has been established at least 4 weeks prior to study entry and is continued throughout the study.~Exclusion Criteria:~* -Significant stress incontinence or mixed stress/urge incontinence where stress is the predominant factor~* Evidence of urinary tract infection; chronic inflammation such as interstitial cystitis and bladder stones~* Clinically significant outflow obstruction (benign prostatic hyperplasia)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Add-on Effects of Tiotropium Over Formoterol in Exercise Tolerance on Chronic Obstructive Pulmonary Disease Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* COPD patients aged ≥ 40 years with stable moderate-to-severe airflow obstruction (FEV1 \< 70% and FEV1/FVC ≤ 70% of predicted normal value) post-bronchodilator~* presenting with a long history of smoking (\> 20 pack-years) and chronic breathlessness (Baseline Dyspnoea Index total score \< 9)~Exclusion Criteria:~* significant cardiovascular disease, hospitalization for COPD exacerbation or presence of a respiratory tract infection within 1 month of screening~* current or childhood asthma~* a history of allergic rhinitis or other atopic disease~* inability to interrupt usual bronchodilator medication~* use of oral steroids within a month before screening~* need for long-term oxygen therapy, arterial oxygen saturation \< 85% at rest anemia, hypo- and hyperthyroidism, hyperadrenergic state~* uncontrolled insulin dependent diabetes mellitus, malignancy, or any disease or condition which limits exercise performance other than COPD~* change in inhaled corticosteroid or theophylline use within 1 month prior to screening

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Formoterol plus Placebo (Tiotropium)
- 2 (Type: EXPERIMENTAL): Formoterol plus Tiotropium

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pioglitazone as a Treatment for Lipid and Glucose Abnormalities In Patients With Schizophrenia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients will be males or females, 18-70 yrs of age, with a diagnosis of schizophrenia or schizoaffective disorder, and currently being treated with olanzapine or clozapine.~2. Patients will have evidence of:~   1. glucose levels indicating at least impaired fasting glucose: fasting glucose 100 mg/dL or 2 hr glucose tolerance test 140 mg/dL, or current treatment with oral antidiabetic drugs with history of hyperglycemia;~  2. Triglyceride levels \> 120 mg/dL and/or HDL levels \< 40 mg/dL~Exclusion Criteria:~1. Diabetes mellitus, type 1~2. Recent diabetic ketoacidosis;~3. Patients not currently treated with oral antidiabetic drugs but fasting is glucose 140 mg/dL \[WHO criteria\] on repeat testing in last three months, or random blood glucose \>200 mg/dL plus 2 hr glucose on GTT \>200 mg/dL; (these patients may need more immediate treatment with antidiabetic drugs and it is less certain if weight-lifestyle treatment would be effective in treating such high glucose levels);~4. Patients with active liver disease with clinical abnormalities which need current treatment, or liver enzymes (Alt) 3 times upper limit for normal values in chart records in last year, or patients who are recorded as positive for hepatitis C;~5. Congestive heart failure (Class III or IV cardiac status) or history of MI in medical record (because pioglitazone can increase blood volume slightly);~6. Hematocrit greater than 10% below normal (hematocrit may be decreased 2 to 4% due to increased plasma volume);~7. Female patients on current oral contraceptives (because pioglitazone may interfere with effects of some oral contraceptives);~8. Patients taking ketoconazole,~9. Patients who have started on atorvastatin or gemfibrozil in the past 2 months or have had a dose increase in atorvastatin in the last month (since these drugs can also lower triglycerides and raise HDL, recent start of therapy with these drugs could be a confound).~10. Patients are not concomitantly treated with aripiprazole or ziprasidone.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Pioglitazone and life-style group (Type: ACTIVE_COMPARATOR): Pioglitazone (30-45 mg/daily) plus life-style diet group
- Placebo and life style group (Type: PLACEBO_COMPARATOR): Placebo capsules daily plus life-style diet group

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Treatment of High-Risk Moderate Acute Malnutrition Using Expanded Admission Criteria

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* uncomplicated MAM (based on MUAC equal to or greater than 11.5 cm and \<12.5)~Exclusion Criteria:~* currently involved in another research trial or feeding program~* medical complication such as oedema, severe nausea/vomiting, severe dehydration, or severe pneumonia~* have a diagnosed or visible sign of developmental delay~* have a history of peanut or milk allergy

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 59 Months
- Healthy Volunteers: f

Study Arms:
- Moderate Acute Malnutrition (MAM) (Type: OTHER): MAM children at control clinics or MAM children at intervention clinics that do no have high rick characteristics. Control treatment is Mother Care counselling, delivered by a respected elder in the local community.
- High Risk Moderate Acute Malnutrition (MAM) (Type: EXPERIMENTAL): The intervention treatment incorporates Mother Care counselling, provision of one packet (508 calories) of ready-to-use therapeutic food (RUTF) daily and a 1 week course of amoxicillin. This provision will continue until the child has reached a mid-upper arm circumference (MUAC) equal to or greater than 12.5 cm or 12 weeks have elapsed.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Optimal Dose of Irbesartan for Renoprotection in Type 2 Diabetic Patients With Persistent Microalbuminuria

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Type 2 diabetes (WHO criteria) and age above 18 years.~* Persistent microalbuminuria (urinary albumin excretion between 30 and 300 mg/24-h in at least two out of three 24-urinary collections~* Systolic blood pressure \> 110 mmHg~Exclusion Criteria:~* Serum creatinine \> 150 micromol/l~* Known non-diabetic renal disease~* Pregnancy or fertile women not using adequate contraception (intrauterine device, sterilization or oral anticonception)~* Systolic blood pressure persistently \> 180 mm Hg or \< 100 mm Hg~* Diastolic blood pressure persistently \> 105 mm Hg~* Plasma potassium \> 4.8 mmol/l~* Heart failure, acute myocardial infarction, unstable angina or coronary by-pass surgery within the previous three months.~* Known intolerance to angiotensin II receptor blockers

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Intravenous Lidocaine and Ketorolac for Pain Management

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Emergency Medicine Patient~* clinical diagnosis of acute renal colic~* pain score of \>=5 out of 10 on the numeric rating scale~* - age 18 - 64 years of age~Exclusion Criteria:~* documented or suspected pregnancy, breastfeeding~* contraindication to nonsteroidal anti-inflammatory drugs or lidocaine~* known renal dysfunction~* received analgesics within 4 hours before presentation~* history of bleeding diathesis~* history of peptic ulcer disease~* current use of warfarin~* HR\<50 or \>150~* history of cardiac arrhythmias~* peritonitis or presence of any peritoneal sign~* altered mental status~* weight \> 100kg

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Study Arms:
- Lidocaine and normal saline push (Type: ACTIVE_COMPARATOR): 1.5mg/kg IV Lidocaine Drip (given over 10 minutes) and normal saline push
- Ketorolac and normal saline drip (Type: ACTIVE_COMPARATOR): IV Ketorolac Tromethamine 30mg push and 10 minute normal saline drip
- Lidocaine and Ketorolac (Type: ACTIVE_COMPARATOR): IV Lidocaine Drip and IV Ketorolac Push

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of SPIL1033 in Subjects With Type 2 Diabetes Mellitus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female subjects 20 years of age and older.~* Established clinical diagnosis of type 2 diabetes mellitus treated with diet and exercise or anti-diabetic agents as monotherapy or combination therapy.~* Weight stable: their weight should not have varied more than 10% of screening visit weight, within 6 months prior to screening visit.~* Women of child bearing potential practicing an acceptable method of birth control as judged by the investigator(s); with a negative urine pregnancy test.~* Willing to participate and give written informed consent.~Exclusion Criteria:~* Previous exposure to exenatide (anti-exenatide antibodies at screening) or a glucagon-like peptide (GLP-1) analogue.~* Used drugs for weight loss (for example, orlistat, sibutramine, phenylpropanolamine, rimonabant, or similar over-the-counter medications) within 3 months of screening.~* Received treatment within the last 30 days with a drug that has not received regulatory approval for any indication at the time of trial entry.~* Severe renal impairment (creatinine clearance \<30 ml/min) or end stage renal disease.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- SPIL1033 (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of the ICG Distribution in the Margins of Breast Cancer After Tumorectomy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with histopathological diagnosis of mammary cancer who are candidate for tumorectomy, either with SLN selective lymphadenectomy, or with complete axillary node dissection,~* Informed consent form signed.~Exclusion Criteria:~* Diagnosis of mammary cancer established by gross biopsy,~* Age less than18 years old.~* Inability to give informed consent.~* History of allergy or hypersensitivity against the investigational product (its active substance or ingredients), to iodine or to shellfish.~* Apparent hyperthyroidism, autonomous thyroid adenoma, unifocal, multifocal or disseminated autonomies of the thyroid gland.~* Documented coronary disease.~* Advanced renal impairment (creatinine \> 1,5mg/dl).~* During the 2 weeks before the enrolment, concurrent medication which reduces or increases the extinction of ICG (i.e. anticonvulsants, haloperidol and Heparin).~* Pregnancy, breastfeeding

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Indocyanine Green (Type: EXPERIMENTAL): study of the correlation between fluorescence and margins of the tumours after iv injection of Indocyanine Green

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Calcium for Prevention of Ovarian Hyperstimulation Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* infertile women aged 20 to 38 years.~* BMI ranged from 18 to 40.~* serum FSH within normal limits( 1-12IU /l)~* presented with ovarian response suggestive of being at risk of developing OHSS because of the presence of at least 15 follicles of 10 mm or greater on the day of hCG administration.~Exclusion Criteria:~* endocrinopathies.~* a systemic disease.~* using any medication (e.g., insulin-sensitizing drugs and GnRH antagonists.~* patients need coasting for high risk of OHSS.~* patients need cycle cancellation.~* severe male infertility requiring testicular sperm extraction.

- Gender: FEMALE
- Minimum Age: 20 Years
- Maximum Age: 38 Years
- Healthy Volunteers: t

Study Arms:
- saline (Type: PLACEBO_COMPARATOR): 0.9% saline intravenous infusion
- calcium (Type: EXPERIMENTAL): Calcium intravenous infusion

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Impact of Dexmedetomidine on Sleep Quality

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age \>= 65 years~2. Scheduled to undergo elective non-cardiac major surgery (with expected duration \>= 2 hours) under general anesthesia~3. Transferred to general ward with a patient-controlled intravenous analgesia pump after surgery.~Exclusion Criteria:~1. Refuse to participate~2. Preoperative history of schizophrenia, epilepsy, parkinsonism or myasthenia gravis~3. Patients with preoperative sleep disorders (accepted sedatives or hypnotics within 1 month before surgery) or the STOP-BANG Questionnaire score is 3 or higher~4. Inability to communicate in the preoperative period because of coma, profound dementia or language barrier~5. Brain injury or neurosurgery~6. Preoperative left ventricular ejection fraction \< 30%, sick sinus syndrome, severe sinus bradycardia (\< 50 beats per minute), or second-degree or above atrioventricular block without pacemaker~7. Severe hepatic dysfunction (Child-Pugh class C); Severe renal dysfunction (requirement of renal replacement therapy before surgery); ASA classification IV or unlikely to survive for more than 24 hours after surgery~8. Patients recruited in other studies~9. Other conditions that are considered unsuitable for study participation

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Dexmedetomidine group (Type: EXPERIMENTAL): Morphine (0.5 mg/ml, in a total volume of 160 ml) is used for patient-controlled analgesia. Dexmedetomidine (200 ug) is added to the formula of patient-controlled analgesia. Patient-controlled analgesia is provided during the first 3 days after surgery.
- Placebo group (Type: PLACEBO_COMPARATOR): Morphine (0.5 mg/ml, in a total volume of 160 ml) is used for patient-controlled analgesia. Placebo (normal saline) is added to the formula of patient-controlled analgesia. Patient-controlled analgesia is provided during the first 3 days after surgery.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Benefit of Local Anesthesia at the Sternum in Patients With Coronary Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients undergoing coronary artery bypass graft requiring sternotomy other than re-interventions and combined surgeries~* Consent for participation~* Affiliation to the french social security system~Exclusion Criteria:~* Pregnant or breastfeeding women~* Patients under protection of the adults (guardianship, curator or safeguard of justice)~* Communication difficulties or neuropsychiatric disorder~* Neuropathic disease~* Constitutional coagulation disorders~* Kidney insufficiency~* Sensitivity to nonsteroidal anti-inflammatory drugs~* Hypersensitivity to local anaesthetics~* Chronic use of opioid analgesics~* Corticosteroid treatment or immunosuppressive therapy~* Autoimmune disease~* Chronic pain syndrome or fibromyalgia~* Emergency cardiac surgery~* Hypovolemia

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- parasternal block (Type: EXPERIMENTAL): preoperative parasternal block by ropivacaine injection
- physiological serum (Type: PLACEBO_COMPARATOR): sodium chloride injection

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete